Developing an antibody against a viral antigen presents unique challenges, particularly due to the high risk of viral escape and the need for specialized strategies, such as those required for generating neutralizing antibodies.
With over 20 years of experience and hundreds of successful antibody developments against viral targets, ProteoGenix has designed tailored tools and strategies to optimize every step of the process—from antigen selection to customized protocols for neutralizing antibody discovery.

Why choose ProteoGenix services for the development of monoclonal antibodies against viral targets?

A risk-free investment

We integrate multiple guarantees into our services, minimizing your financial risks.

Exclusive access to advanced technologies

Benefit from our latest research advancements, including proprietary phage display libraries, high-throughput technologies, and AI-driven antibody discovery solutions.

Save up to 3 weeks with ready-to-use viral antigens

ProteoGenix offers a proprietary catalog of viral antigens and antibodies for therapeutic research, significantly accelerating your antibody development timeline.

Hundreds of antibodies produced

Whether for our clients or our own catalog, we have developed hundreds of antibodies against viral targets.

Skip the lengthy humanization phase

Our fully human antibody generation services can save you up to six months of development time.

End-to-end solutions

Choose a unique partner for all your therapeutic antibody discovery services.

Request a free consultation

Challenges in developing antibodies against viral targets and our solutions

Antigens with high mutation rates

One of the main challenges in developing antibodies against viral targets is their ability to mutate rapidly. These mutations occur through various mechanisms, such as replication errors, selective pressure, recombination, or reassortment, potentially reducing antibody efficacy. Therefore, selecting a highly conserved antigen is a key factor in antibody discovery.
Cryptic epitopes are often considered less prone to mutations but can be difficult to access. To increase the chances of targeting these epitopes, ProteoGenix has developed a specialized VHH library tailored for such projects.

Strategies for generating highly specific neutralizing antibodies

In many cases, the goal of viral antibody development is to generate neutralizing antibodies, which block viral infection by preventing host cell attachment, inhibiting membrane fusion, or stopping viral genome release.
At ProteoGenix, we combine multiple antibody discovery technologies (such as a dedicated antibody library generated from COVID-19 survivors) with a dedicated phage display protocol designed specifically for neutralizing antibody discovery. This approach ensures that the antibodies we deliver effectively bind to the antigen-ligand interaction site, guaranteeing strong neutralizing activity.

Solutions to overcome viral escape

A major challenge in antiviral antibody development is viral escape, where mutations render previously effective antibodies ineffective. To mitigate this risk, antibodies can be developed against highly conserved antigens or designed as antibody cocktails (oligoclonal antibodies) that target multiple epitopes simultaneously.
A successful example of this approach is detailed below.

Request a free consultation

Success Story: development of an antibody cocktail against SARS-CoV-2

During the COVID-19 pandemic, ProteoGenix collaborated with Trident Biopharm Solutions and Aseem Healthcare to develop monoclonal antibodies effective against multiple SARS-CoV-2 variants.

Download our case study to discover:

  • The strategy used to generate antibodies effective against different SARS-CoV-2 variants
  • The results of our human immune phage display library construction
  • The panning and screening strategies for identifying the best candidates
  • The recombinant antibody production results using our proprietary XtenCHO system
  • The neutralization test results

    Client testimonial

    “I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage Display. They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns. During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemic evolved. Their proactivity was key to obtaining promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.”

    This project was featured in a joint press release with our client.

    Frequently asked questions